Natural History of Type 1 Diabetes (T1 DM)

Similar documents
Chapter 3 Type 1 Diabetes

Etiology of Type 1 Diabetes Chris Theberge

Viral Hepatitis Case Report

Newborn Genetic Screening for Type 1 Diabetes: Impact on Families. Suzanne Bennett Johnson Florida State University College of Medicine

The Gut Immune System and Type 1 Diabetes

Autoimmunity and immunemediated. FOCiS. Lecture outline

TrialNet Natural History Study of the Development of Type 1 Diabetes: A Pathway to Prevention

Autoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

The Danish Bone Marrow Donor Registry DBMDR

The donor search: the best donor or cord blood unit

Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals

Preamble. 1. If it is necessary, are you willing to receive follow up questions to help clarify any answers to the survey questions?

Why use passive immunity?

HISTO TYPE SSP Immunogenetic Diagnostics. Robust and fast - validated Taq Polymerase included

Nutritional risk predictors of cell autoimmunity and type 1 diabetes at a young age 1,2

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

Nutrition and Toxicants in Autoimmune Disease: Implications for Prevention and Treatment

Immunity and how vaccines work

Viral Hepatitis APHL survey report

Type 1 diabetes is a chronic inflammatory disease

Diabetes Mellitus Type1

Selective IgA deficiency (slgad)

HBV DNA < monitoring interferon Rx

GAW 15 Problem 3: Simulated Rheumatoid Arthritis Data Full Model and Simulation Parameters

Core Topic 2. The immune system and how vaccines work

BVD qpcr Bulk Milk Test

DNA as a Biometric. Biometric Consortium Conference 2011 Tampa, FL

Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

TYPE 1 DIABETES MELLITUS (DM)

14/12/2012. HLA typing - problem #1. Applications for NGS. HLA typing - problem #1 HLA typing - problem #2

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Approaches in type 1 diabetes research: A status report

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Global Under Diagnosis of Viral Hepatitis

Figure 14.2 Overview of Innate and Adaptive Immunity

Chapter 43: The Immune System

HLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of

How Does a Doctor Test for AIDS?

INTERPRETATION INFORMATION SHEET

Viral load testing. medical monitoring: viral load testing: 1

Genetics of Rheumatoid Arthritis Markey Lecture Series

How To Test For Islet Autoantibodies

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

How to construct transgenic mice

Chapter 3. Immunity and how vaccines work

INSULIN-DEPENDENT (TYPE 1) DIABETES MELLITUS

Objectives: Immunity Gone Wrong: Autoimmune Diseases in Dental Hygiene Practice

Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia

A trait is a variation of a particular character (e.g. color, height). Traits are passed from parents to offspring through genes.

Population Genetics and Multifactorial Inheritance 2002

Antibody Structure, and the Generation of B-cell Diversity CHAPTER 4 04/05/15. Different Immunoglobulins

Genetic Engineering and Biotechnology

Immunogenetics of type 1 diabetes mellitus

NURSING STUDENT HEALTH & IMMUNIZATION RECORDS

A n n u a l R e p o r t

Addition of vaccination against hepatitis B infection and change of the HPV vaccination programme

Parvovirus B19 Infection in Pregnancy

Transient Hypogammaglobulinemia of Infancy. Chapter 7

DENTAL ASSISTANT PROGRAM PROGRAM REQUIREMENT PACKET

Epstein Barr Virus (EBV) Serological Diagnosis of Epstein Barr Virus. Epstein Barr Virus (EBV) Epstein Barr Virus (EBV)

QUICK REFERENCE TO BLOOD BANK TESTING

Environmental Triggers and Determinants of Beta-Cell Autoimmunity and Type 1 Diabetes

The Polio Virus. Getting to Know Your Old Enemy. Marcia Falconer, Ph.D.

Chapter 18: Applications of Immunology

Case Finding for Hepatitis B and Hepatitis C

Annex to the Accreditation Certificate D-PL according to DIN EN ISO/IEC 17025:2005

Human Leukocyte Antigens - HLA

Transmission of HCV in the United States (CDC estimate)

Lupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital

On April 4, a group of physicians at the 37th annual

HISTO SPOT SSO System. The most convenient automated HLA typing system. BAG Health Care the experts for HLA and blood group diagnostics

Seroprevalence and risk factors of Lassa fever infection in Nasarawa State, Nigeria 2013

Testimony to Minnesota Legislature April 28, 2011 Theresa A. Deisher, Ph.D.

Appendix 3 Exposure Incident Report Form

Rheumatoid arthritis: an overview. Christine Pham MD

A Genetic Analysis of Rheumatoid Arthritis

YMCA OF GREATER NEW YORK SUMMER CAMP REGISTRATION FORM

Gene Mapping Techniques

Chickenpox and Shingles Vaccines

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

Association between immune reactivity and disease status of type 1, type 2 diabetes and latent autoimmune diabetes in adults

Review: How to work up your patient with Hepatitis C

ROLE OF ANTIBODIES TO GLUTAMIC ACID DECARBOXYLASE IN TYPE 1 DIABETES Relation to other autoantibodies, HLA risk markers and clinical characteristics

HISTO SPOT SSO System. The most convenient automated HLA typing system. BAG Health Care the experts for HLA and blood group diagnostics

Basics of Immunology

Early HIV- specific CD8 + T cell responses in treated and untreated hyper acute HIV infec=on in the FRESH cohort

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

Clinically Actionable Biomarkers in Rheumatoid Arthritis

Food Allergy Gluten & Diabetes Dr Gary Deed Mediwell 314 Old Cleveland Road Coorparoo

Hepatitis B Virus (Pregnancy) Investigation Guideline

Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Review of the Prevalence of Type 1 Diabetes among Children and Adolescents in Weston, Wellesley and Newton

AAV specific issues pertaining to vector shedding in gene therapy clinical trials. Samuel Wadsworth Genzyme Corporation

Holy Family University, Student Health Services, Directions for Completion of Health Packet

Transcription:

Natural History of Type 1 Diabetes (T1 DM) Initiators - virus? - diet? Promoters - genes? - virus? - diet? Genetic susceptibility Islet Autoimmunity Clinical diabetes No autoimmunity No progression Remission

Islet Autoimmunity (IA) Definition IAA, GAD or ICA512 (IA-2) positive on at least two consecutive visits including the last visit or positive once before developing diabetes (would be nice to have a good T-cell assay or beta-cell mass measure )

Incidence of Type 1 diabetes /100,000/yr 35 30 25 20 15 10 5 DAISY to date NHW Hispanic DAISY proposed f-up 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Colorado IDDM Registry, 1978-88 Age [years]

IDDM Loci Confirmed in Recent Genome Screens IDDM Marker Chromosome LOD IDDM1 MHC 6p21.3 65.8, 39.4* IDDM2 Insulin 11p15.5 4.28 IDDM15 D6S283 6q21 2.36, 3.12* IDDM10 10p13-q11 2.8 IDDM7 2q31 2.62 D16S3098 16q 4.23 16p* 2.34* 1q42 2.27 2* 2.1* 5* 2.1* Concannon et al. 768 families *Julier et al. 485 sib pairs

HLA-DR,DQ genotypes in Colorado T1 DM patients (n=1,509) 60% 50% DAISY to date DR3/4,DQB1*0302 DAISY proposed f-up 40% 30% DR4/4, 4/x, DQB1*0302 20% 3/3, 3/x 10% x/x 0% 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 years

Univ. Colorado Roche Molecular Systems Alameda Denver CDC NIDDK NIAID DAISY Diabetes AutoImmunity Study in the Young

Diabetes Autoimmunity Study in the Young General population cohort Sibling/offspring cohort screened = 23,305 enrolled = 349 high risk 83 448 moderate risk 230 347 average - low risk 500 1,144 All 813 relatives 1,491 1,007 7/01

General Population HLA screening DAISY 1999 + HLA-DR,DQ % RR 3/4, 0302 (not *0403,6) 2.1 26 4/4, 0302 (not *0403,6) 2.4 11 4/1, 8, 9 or 13 (not *0403,6) 3.4 6 3/3 1.5 4 9.4% Add IDDM2, CTLA-4, other HLA- and non-hla markers?

DAISY Strip (18 BSA-SSO probes) for DRB1 and DQB1 Epitopes: W L F W P R Y S T S V H Y S T G G Y K K D F E E V K G R R- E E R H F H V D N Y C V D T Y C G V L G P P A E G T R A D Q B 1 A L L DR Type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 X X +/- +/- X 2 (0602) X X +/- +/- X X 2# X X +/- +/- X 3 X X X +/- +/- X 4 (0302) X X +/- +/- X X 4* X X +/- +/- X 0403/06/11 X X X X +/- X 0407 X X X X +/- X 11/13/14 X +/- X +/- +/- +/- +/- X 12 X X X +/- X 7 X X X 8/1404/1411 X X +/- +/- +/- X 9 X X X 10 X X X X

General Population High/Moderate-Risk Cohort Follow-up Protocol (N=5,200) Interviews: diet, infections, immunizations allergies, stress B 3m 6m 9m 1y 15m 2y 3y etc Clinical Visits: blood sample for GAA, IAA, ICA512, DNA throat and rectal swabs, saliva sample

Autoantibody development in a sibling HLA-DR3/4,DQB1*0302 DAISY ID 00060 1000.0 100.0 SD score ECHO16 GAA IAA ICA512 TGIgA 10.0 1.0 0.1 0.8 1.1 1.4 1.8 2.4 2.7 3.0 3.3 3.6 3.8 4.2 4.9 5.4 6.1 6.7 7.3 7.9 8.4 EV- + - + + - + + Age [yrs]

Intensive follow-up protocol (N=500) Siblings & offspring, DR3/4,DQB1*0302, DR4/4, DR 3/3 Filter Paper Blood: GAA, IAA, IA-2, viral antibodies Cord blood 0 1 2 3 4 5 6 7 8 9 12 15 18 21 24 27 31 33 36, etc. months Clinic Visits: blood for GAA, IAA, IA-2, viral antibodies, DNA T-cell studies throat & rectal swabs, saliva samples, interviews

Risk of diabetes in siblings and offspring 100% Autoimmunity free survival 80% 60% 40% DAISY, 10/01 20% 0% No antibodies Antibody + Age [yr] 0 1 2 3 4 5

Remission in a HLA-DR4/x sibling HLA-DR4/x, DAISY ID 00130 100.0 10.0 SD score GAA IAA ICA512 1.0 0.1 2.1 2.4 2.7 2.9 3.3 3.7 4.3 5.3 6.3 7.7 8.7 EV- EV- EV- EV- EV- EV- EV- Age [yrs]

Early childhood diet and T1 DM?

Associations between exposure to specific foods in the infant diet and risk of BCA Exposed by 6 Months to: Cases (n = 27) Controls (n = 1022) P-value Hazard ratio (95% CI) Cereal 77.8% 92.9% 0.003 0.29 (0.12-0.72) Gluten 33.3% 58.3% 0.01 0.41 (0.18-0.92) Fruits/vegetables 70.4% 83.5% 0.11 0.42 (0.18-0.96) Cow s milk 74.1% 75.4% 0.87 1.17 (0.49-2.79) Meat 22.2% 15.8% 0.42 1.46 (0.58-3.61) Norris et al. DAISY, 10/00

Infections and T1 DM?

Enteroviruses - recent studies Study Autoimmunity Diabetes Frisk 1992, Dahlquist 1995 CVB 1-5 IgM Hyoty 1995 IgM, IgG CVB CVB IgM, IgG Hiltunen 1997 Clements 1995 EV RNA Andreoletti 1997 Graves (DAISY) 1996, 1998 - EV RNA - EV RNA - EV IgM Lonnrot 2000 + EV RNA - EV RNA

PCR-detected EV infections during a 6-months prior to development of islet autoantibodies 40% 20% OR=0.3, NS n=26 n=39 OR=8.4; 1.7-40 n=21 n=104 Cases Controls 0% DAISY DIPP

1000.0 100.0 Autoantibody development in a sibling with HLA-DR3/4,DQB1*0302 DAISY ID 00132 SD score GAA IAA ICA512 10.0 DIABETES 1.0 ECHO16 0.1 0.8 1.1 1.3 1.9 2.2 2.4 2.7 2.8 3.8 EV- EV- EV+ EV- EV- EV- EV+ Age [yrs]

Immunizations and Type 1 diabetes P. Graves at al, DAISY 1998 There was no difference between cases or controls in the timing or number of doses of Polio, DTP or MMR vaccines. There was no difference between cases and controls in the proportion receiving HBV, receiving HBV at birth, or age at first HBV. There was a trend towards earlier Hib immunization in cases. There is no suggestion that earlier administration of childhood vaccines would prevent BCA or type 1 DM. DAISY 1998

A future multi-center study General population cohort Sibling/offspring cohort 3-4 centers, NHW, AA, Hisp., other 4-5 centers (TrialNet, others) screen = 100,000 /2-3 yrs screen = 5,000 enroll = 1,500 (75%) high risk enroll = 300 (60%) 3,700 (50%) moderate risk 200 (40%) 3,120 /5,200 (60%) 15-yr f-up 400 / 500 (80%) 200 / 100 cases IA/DM 120 / 80 10,000 Parents 1,000

DAISY follow-up participation rates 00% 80% Siblings/offspring General Population High-risk 60% 40% General Population Moderate-risk 20% 0% 0 1 2 3 4 5 6 Age [yr]